Synonym
Mianserin hydrochloride; Tolvon; Tolvin; ORG GB 94; Lerivon; Mianserine hydrochloride
IUPAC/Chemical Name
2-methyl-1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine hydrochloride
InChi Key
YNPFMWCWRVTGKJ-UHFFFAOYSA-N
InChi Code
InChI=1S/C18H20N2.ClH/c1-19-10-11-20-17-9-5-3-7-15(17)12-14-6-2-4-8-16(14)18(20)13-19;/h2-9,18H,10-13H2,1H3;1H
SMILES Code
CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42.Cl
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
Mianserin hydrochloride (Org GB 94) is a H1 receptor inverse agonist and is a psychoactive agent of the tetracyclic antidepressant.
In vitro activity:
Effects of mianserin were examined in CHO cells transfected with human opioid receptors, C6 glioma cells and rat brain membranes by the use of radioligand binding and functional assays including the stimulation of [(35)S]GTPγS binding and MAPK phosphorylation. Mianserin displayed 12- and 18-fold higher affinity for κ- than µ- and δ-opioid receptors respectively. In [(35)S]GTPγS assays, mianserin selectively activated κ-opioid receptors. Mianserin and mirtazapine increased ERK1/2 phosphorylation in CHO cells expressing κ-opioid receptors and C6 cells, and these effects were antagonized by nor-BNI.
Reference: Br J Pharmacol. 2012 Nov;167(6):1329-41. https://pubmed.ncbi.nlm.nih.gov/22708686/
In vivo activity:
This study used various experimental pain methods to investigate the effects of subacute mianserin administration on diabetes-induced neuropathic pain in rats. At 30 and 45 mg/kg, mianserin effectively improved mechanical and thermal hyperalgesia occurring in connection with diabetic neuropathy. Subacute administration of mianserin also reduced diabetes-associated mechanical and thermal allodynia. The ability of mianserin to reduce diabetic neuropathic pain was comparable to that of pregabalin (10mg/kg). These results suggest that the beneficial effect of mianserin on diabetic neuropathic pain is mediated through an increase in catecholamine levels in the synaptic cleft as well as through interactions with both subtypes of adrenoceptors and opioid receptors.
Reference: Eur J Pharmacol. 2015 Jun 5;756:92-106. https://pubmed.ncbi.nlm.nih.gov/25771454/
|
Solvent |
mg/mL |
mM |
comments |
| Solubility |
| DMSO |
55.0 |
182.83 |
|
| Ethanol |
21.0 |
69.81 |
|
| Water |
19.3 |
64.28 |
|
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
300.83
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Okura T, Ohkawara B, Takegami Y, Ito M, Masuda A, Seki T, Ishiguro N, Ohno K. Mianserin suppresses R-spondin 2-induced activation of Wnt/β-catenin signaling in chondrocytes and prevents cartilage degradation in a rat model of osteoarthritis. Sci Rep. 2019 Feb 26;9(1):2808. doi: 10.1038/s41598-019-39393-x. Erratum in: Sci Rep. 2020 Feb 14;10(1):2995. PMID: 30808932; PMCID: PMC6391487.
2. Olianas MC, Dedoni S, Onali P. The atypical antidepressant mianserin exhibits agonist activity at κ-opioid receptors. Br J Pharmacol. 2012 Nov;167(6):1329-41. doi: 10.1111/j.1476-5381.2012.02078.x. PMID: 22708686; PMCID: PMC3504997.
3. Üçel Uİ, Can ÖD, Demir Özkay Ü, Öztürk Y. Antihyperalgesic and antiallodynic effects of mianserin on diabetic neuropathic pain: a study on mechanism of action. Eur J Pharmacol. 2015 Jun 5;756:92-106. doi: 10.1016/j.ejphar.2015.02.048. Epub 2015 Mar 11. PMID: 25771454.
4. Manikowska K, Mikołajczyk M, Mikołajczak PŁ, Bobkiewicz-Kozłowska T. The influence of mianserin on TNF-α, IL-6 and IL-10 serum levels in rats under chronic mild stress. Pharmacol Rep. 2014 Feb;66(1):22-7. doi: 10.1016/j.pharep.2013.06.003. Epub 2014 Feb 4. PMID: 24905302.
In vitro protocol:
1. Okura T, Ohkawara B, Takegami Y, Ito M, Masuda A, Seki T, Ishiguro N, Ohno K. Mianserin suppresses R-spondin 2-induced activation of Wnt/β-catenin signaling in chondrocytes and prevents cartilage degradation in a rat model of osteoarthritis. Sci Rep. 2019 Feb 26;9(1):2808. doi: 10.1038/s41598-019-39393-x. Erratum in: Sci Rep. 2020 Feb 14;10(1):2995. PMID: 30808932; PMCID: PMC6391487.
2. Olianas MC, Dedoni S, Onali P. The atypical antidepressant mianserin exhibits agonist activity at κ-opioid receptors. Br J Pharmacol. 2012 Nov;167(6):1329-41. doi: 10.1111/j.1476-5381.2012.02078.x. PMID: 22708686; PMCID: PMC3504997.
In vivo protocol:
1. Üçel Uİ, Can ÖD, Demir Özkay Ü, Öztürk Y. Antihyperalgesic and antiallodynic effects of mianserin on diabetic neuropathic pain: a study on mechanism of action. Eur J Pharmacol. 2015 Jun 5;756:92-106. doi: 10.1016/j.ejphar.2015.02.048. Epub 2015 Mar 11. PMID: 25771454.
2. Manikowska K, Mikołajczyk M, Mikołajczak PŁ, Bobkiewicz-Kozłowska T. The influence of mianserin on TNF-α, IL-6 and IL-10 serum levels in rats under chronic mild stress. Pharmacol Rep. 2014 Feb;66(1):22-7. doi: 10.1016/j.pharep.2013.06.003. Epub 2014 Feb 4. PMID: 24905302.
1: Haine SE, Miljoen HP, Blankoff I, Vrints CJ. Mianserin and ventricular tachycardia: case report and review of the literature. Cardiology. 2006;106(4):195-8. Epub 2006 May 3. Review. PubMed PMID: 16675906.
2: Rotzinger S, Bourin M, Akimoto Y, Coutts RT, Baker GB. Metabolism of some "second"- and "fourth"-generation antidepressants: iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine. Cell Mol Neurobiol. 1999 Aug;19(4):427-42. Review. PubMed PMID: 10379419.
3: Poyurovsky M, Schneidman M, Weizman A. Successful treatment of fluoxetine-induced dystonia with low-dose mianserin. Mov Disord. 1997 Nov;12(6):1102-5. Review. PubMed PMID: 9399252.
4: Leinonen E, Koponen H, Lepola U. Serum mianserin and ageing. Prog Neuropsychopharmacol Biol Psychiatry. 1994 Sep;18(5):833-45. Review. PubMed PMID: 7972855.
5: Demling J. [Mianserin: pharmacology and clinical aspects of an effective antidepressive agents]. Fortschr Med. 1993 Nov 10;111(31):497-500. Review. German. PubMed PMID: 8276338.
6: Tiraboschi P. [Mianserin]. Medicina (Firenze). 1988 Jul-Sep;8(3):351-3. Review. Italian. PubMed PMID: 3068469.
7: Mianserin 10 years on. Drug Ther Bull. 1988 Mar 7;26(5):17-8. Review. PubMed PMID: 3286177.
8: Boschmans SA, Perkin MF, Terblanche SE. Antidepressant drugs: imipramine, mianserin and trazodone. Comp Biochem Physiol C. 1987;86(2):225-32. Review. PubMed PMID: 2882911.
9: Chaplin S. Bone marrow depression due to mianserin, phenylbutazone, oxyphenbutazone, and chloramphenicol--Part II. Adverse Drug React Acute Poisoning Rev. 1986 Autumn;5(3):181-96. Review. PubMed PMID: 3538824.
10: Chaplin S. Bone marrow depression due to mianserin, phenylbutazone, oxyphenbutazone, and chloramphenicol--Part I. Adverse Drug React Acute Poisoning Rev. 1986 Summer;5(2):97-136. Review. Erratum in: Adverse Drug React Acute Poisoning Rev 1986 Winter;5(4):233. PubMed PMID: 3529881.
11: Lingjaerde O. From clomipramine to mianserin: therapeutic relevance of interactions with serotonin uptake and storage, as studied in the blood platelet model. Acta Psychiatr Scand Suppl. 1985;320:10-9. Review. PubMed PMID: 3901671.
12: Pinder RM. Adrenoreceptor interactions of the enantiomers and metabolites of mianserin: are they responsible for the antidepressant effect? Acta Psychiatr Scand Suppl. 1985;320:1-9. Review. PubMed PMID: 2996305.
13: Wakeling A. Efficacy and side effects of mianserin, a tetracyclic antidepressant. Postgrad Med J. 1983 Apr;59(690):229-31. Review. PubMed PMID: 6346303; PubMed Central PMCID: PMC2417496.
14: De Ridder JJ. Mianserin: result of a decade of antidepressant research. Pharm Weekbl Sci. 1982 Oct 22;4(5):139-45. Review. PubMed PMID: 6128715.
15: Pinder RM, Fink M. Mianserin. Mod Probl Pharmacopsychiatry. 1982;18:70-101. Review. PubMed PMID: 7048075.
16: Cassano GB, Conti L, Dell'Osso L, Massimetti G. Four new atypical antidepressants (trazodone, mianserin, nomifensine, caroxazone): results of controlled trials. Adv Biochem Psychopharmacol. 1982;32:125-39. Review. PubMed PMID: 7046361.
17: Leonard BE. On the mode of action of mianserin. Adv Biochem Psychopharmacol. 1982;31:301-19. Review. PubMed PMID: 6282060.
18: Montgomery SA. Maprotiline, nomifensine, mianserin, zimelidine: a review of antidepressant efficacy in in-patients. Neuropharmacology. 1980 Dec;19(12):1185-90. Review. PubMed PMID: 6449677.
19: Brogden RN, Heel RC, Speight TM, Avery GS. Mianserin: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs. 1978 Oct;16(4):273-301. Review. PubMed PMID: 359311.
